Investigating the prediction value of multiparametric magnetic resonance imaging at 3 T in response to neoadjuvant chemotherapy in breast cancer.
Investigating the prediction value of multiparametric magnetic resonance imaging at 3 T in response to neoadjuvant chemotherapy in breast cancer.
复制标题
DOI：
10.1007/s00330-016-4565-2
复制
发表时间：
2017-05
影响因子：
5.9
通讯作者：
Gruber S
中科院分区：
文献类型：
--
作者：
Minarikova L;Bogner W;Pinker K;Valkovič L;Zaric O;Bago-Horvath Z;Bartsch R;Helbich TH;Trattnig S;Gruber S
探讨乳腺癌新辅助化疗（NACT）中不同时间点弥散加权成像（DWI）和对比增强（CE）-MRI参数的预测价值。获得了机构审查委员会的批准和42名乳腺癌患者的书面知情同意书。在新辅助化疗（NACT）之前和期间的三个不同时间点，使用CE-MRI的肿瘤直径和体积以及从绘制的2D和分割的3D感兴趣区域获得的ADC值对患者进行了研究。使用受试者操作特征分析的曲线下面积（AUC）评估病理完全缓解（pCR）的预测。病理完全缓解和非pCR之间基线尺寸测量无显著差异（p > 0.39）。在治疗中点之前，pCR的直径变化有显著差异（p < 0.02）。最佳预测因子是治疗中期前观察到的病变直径变化（AUC = 0.93）。在任何时间点，分段体积均无法区分pCR和非pCR。3D-ROI的ADC值与2D数据无显著差异（p = 0.06）。使用DWI预测pCR的最佳AUC（0.79）是NACT中期治疗前测量的中位ADC。NACT监测计划，尤其是MRI方案设计和时间点选择应考虑本研究结果。·治疗中期直径变化是新辅助化疗中pCR的最佳预测因子。 ·在治疗监测中，体积测量并不严格优于病变直径的上级测量。 ·尺寸测量作为比ADC值更好的预测器。
To explore the predictive value of parameters derived from diffusion-weighted imaging (DWI) and contrast-enhanced (CE)-MRI at different time-points during neoadjuvant chemotherapy (NACT) in breast cancer. Institutional review board approval and written, informed consent from 42 breast cancer patients were obtained. The patients were investigated before and at three different time-points during neoadjuvant chemotherapy (NACT) using tumour diameter and volume from CE-MRI and ADC values obtained from drawn 2D and segmented 3D regions of interest. Prediction of pathologic complete response (pCR) was evaluated using the area under the curve (AUC) of receiver operating characteristic analysis. There was no significant difference between pathologic complete response and non-pCR in baseline size measures (p > 0.39). Diameter change was significantly different in pCR (p < 0.02) before the mid-therapy point. The best predictor was lesion diameter change observed before mid-therapy (AUC = 0.93). Segmented volume was not able to differentiate between pCR and non-pCR at any time-point. The ADC values from 3D-ROI were not significantly different from 2D data (p = 0.06). The best AUC (0.79) for pCR prediction using DWI was median ADC measured before mid-therapy of NACT. The results of this study should be considered in NACT monitoring planning, especially in MRI protocol designing and time point selection. • Mid-therapy diameter changes are the best predictors of pCR in neoadjuvant chemotherapy. • Volumetric measures are not strictly superior in therapy monitoring to lesion diameter. • Size measures perform as a better predictor than ADC values.